VTRS · Earnings call · 2026Q2T · Full report
Guidance and Outlook
Viatris Inc · 2026-08-06 · Importance 62 · Surprise 68 · In source text
Viatris raised the midpoint of its 2026 guidance ranges for total revenue, adjusted EBITDA and adjusted EPS. The revised midpoints imply approximately 2% operational revenue growth, 5% adjusted EBITDA growth and 7% adjusted EPS growth versus 2025. Full-year expectations include low-double-digit Greater China growth, roughly flat developed-markets revenue, low-single-digit emerging-markets growth and a low-single-digit JANZ decline. Second-half revenue is expected to represent approximately 51% of the full-year outlook, while adjusted EBITDA and adjusted EPS are expected to be slightly lower in the second half.
Key facts
- Midpoint of revised 2026 guidance represents expected operational growth vs prior year of approximately 2% total revenues, 5% adjusted EBITDA and 7% adjusted EPS
- Viatris believes fast-acting meloxicam could reach up to $500 million in peak sales with potential market exclusivity that could extend beyond three years
- Adjusted EBITDA and adjusted EPS are now expected to be slightly lower in the second half of 2026
- Viatris expects results from both Phase III SLE studies OPUS-1 and OPUS-2 for cenerimod in the first half of 2027
- Adjusted EBITDA expected to come in above the midpoint of guidance for full-year 2026 despite anticipated second-half challenges
- Total revenues are expected to be weighted to the second half at approximately 51% of full year outlook
- Viatris continues to expect a selatogrel data readout in the first half of 2027
- Management guidance: over the coming quarters, the company expects important product launches.
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | committed | — | Midpoint of revised 2026 guidance represents expected operational growth vs prior year of approximately 2% total revenues, 5% adjusted… |
| operating_income | positive | committed | — | Midpoint of revised 2026 guidance represents expected operational growth vs prior year of approximately 2% total revenues, 5% adjusted… |
| net_income | positive | committed | — | Midpoint of revised 2026 guidance represents expected operational growth vs prior year of approximately 2% total revenues, 5% adjusted… |
| revenue | positive | contingent | — | Viatris believes fast-acting meloxicam could reach up to $500 million in peak sales with potential market exclusivity that could extend… |
| operating_income | negative | committed | — | Adjusted EBITDA and adjusted EPS are now expected to be slightly lower in the second half of 2026 |
| net_income | negative | committed | — | Adjusted EBITDA and adjusted EPS are now expected to be slightly lower in the second half of 2026 |
| operating_income | positive | committed | — | Adjusted EBITDA expected to come in above the midpoint of guidance for full-year 2026 despite anticipated second-half challenges |